Molnuva Capsule
Molnupiravir
200mg
NIPRO JMI Pharma Limited
| Pack size | 8's pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 40.00 AED |
Indications
Molnuva Capsule is used for:
Indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. Such risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease.
Adult Dose
Adults
The recommended dose is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days.
Hepatic Impairment
No dose adjustment is required for patients with hepatic impairment
Child Dose
Molnupiravir is not authorized for use in patients who are less than 18 years of age.
Renal Dose
Renal Impairment
No dose adjustment is required for patients with renal impairment
Administration
Can be taken with or without food.
Contra Indications
Hypersensitivity to the active substance or to any of the excipients
Precautions
• Embryo-Fetal Toxicity: Molnupiravir is not recommended for use during pregnancy.
• Bone and Cartilage Toxicity: Molnupiravir is not authorized for use in patients less than 18 years of age because it may affect bone and cartilage growth.
Pregnancy-Lactation
Pregnancy: The use of molnupiravir is not recommended during pregnancy. Advise individuals of childbearing potential to use effective contraception correctly and consistently, as applicable, for the duration of treatment and for 4 days after the last dose of molnupiravir.
Lactation: Breastfeeding is not recommended during treatment and for 4 days after the last dose of molnupiravir. A lactating individual may consider interrupting breastfeeding and may consider pumping and discarding breast milk during treatment and for 4 days after the last dose of molnupiravir.
Interactions
Adverse Effects
Side effects of Molnupiravir :
The most common adverse reactions (≥1% of subjects) reported during treatment and during 14 days after the last dose were
diarrhoea (3%), nausea (2%), dizziness (1%) and headache (1%) all of which were Grade 1 (mild) or Grade 2 (moderate).
Mechanism of Action
Molnupiravir is a prodrug that is metabolised to the ribonucleoside analogue N-hydroxycytidine (NHC) which distributes into cells where it is phosphorylated to form the pharmacologically active ribonucleoside triphosphate (NHC-TP). NHC-TP acts by a mechanism known as viral error catastrophe. NHC-TP incorporation into viral RNA by the viral RNA polymerase, results in an accumulation of errors in the viral genome leading to inhibition of replication.
Note
Molnuva 200mg Capsule manufactured by NIPRO JMI Pharma Limited. Its generic name is Molnupiravir. Molnuva is availble in Bangladesh.
Farmaco BD drug index information on Molnuva Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.